Denmark’s OMX Copenhagen 25 Index on Thursday came within 2 percent of turning positive for the year. The reason? Roughly half the benchmark’s weighting comes from pharma shares, which have proven more resilient than most in a global economy ravaged by the impact of the coronavirus. Green stocks have also boosted the gauge.
That’s put the country’s equity benchmark well above its peers -- the next best performer is the Swiss Market Index, down more than 9 percent. The broader Stoxx Europe 600 Index too remains well below the levels it started the year at, despite a rebound from a March low. The narrower OMX Copenhagen 20 Index, in which Novo Nordisk A/S has a 40 percent weighting, is already up 3.4 percent for the period.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for AMWatch has now started
With your free trial you get:
Full access to all locked articles on AMWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.